论文部分内容阅读
背景与目的尿多酸肽是从健康人尿中分离提取、纯化的一组细胞分化诱导剂。临床前实验表明,尿多酸肽对多种肿瘤具有抑制生长、诱导分化凋亡的作用。本研究拟比较尿多酸肽联合NP方案(长春瑞滨NVB、顺铂DDP)化疗与单纯NP方案治疗晚期非小细胞肺癌(NSCLC)的疗效、生存期及毒性。方法42例晚期NSCLC病例被随机分入尿多酸肽联合NP化疗组与NP化疗组。NP方案NVB25mg/m2静脉滴注第1、8天,DDP75mg/m2静脉滴注第1天,21天为一个周期,化疗2周期。尿多酸肽联合NP化疗尿多酸肽注射液300mL锁骨下静脉置管给药,每天1次,于化疗前7天开始用药,再与NP方案联合治疗2周期,化疗药使用当日停用尿多酸肽。结果尿多酸肽联合NP化疗组有效率为44.4%,NP化疗组有效率为20.0%(P>0.05);尿多酸肽联合NP化疗组中位生存期为9个月,NP化疗组为6个月(P=0.0287)。毒副反应主要为骨髓抑制、胃肠道反应和脱发,二组间差异无统计学意义。结论尿多酸肽联合NP化疗治疗晚期复治NSCLC疗效肯定,毒性可耐受,尤其在延长患者中位生存期方面具有一定优势。
BACKGROUND & OBJECTIVE Urine polyacid peptides are a group of cell differentiation inducing agents isolated and purified from healthy human urine. Preclinical experiments show that uroacitides can inhibit the growth of a variety of tumors and induce differentiation and apoptosis. This study intended to compare the efficacy, survival and toxicity of uroacitides combined with NP regimen (vinorelbine NVB, cisplatin DDP) chemotherapy and simple NP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Forty-two patients with advanced NSCLC were randomly divided into NPG combined with NP chemotherapy group and NP chemotherapy group. NP program NVB25mg / m2 intravenous drip 1,8 days, DDP75mg / m2 intravenous infusion on the first day, 21 days for a cycle of chemotherapy 2 cycles. Urine polyacid peptide combined with NP chemotherapy uric acid peptide injection 300mL subclavian vein catheter administration, once a day, 7 days before chemotherapy began to medication, and then with the NP regimen for 2 cycles, the day of the use of chemotherapy drugs to disable urine Polyacid peptide. Results The effective rate of urinary polyacid peptide combined with NP chemotherapy group was 44.4%, and the effective rate of NP chemotherapy group was 20.0% (P> 0.05). The median survival time of NPY combined with NP chemotherapy group was 9 months 6 months (P = 0.0287). The main side effects were myelosuppression, gastrointestinal reaction and hair loss. There was no significant difference between the two groups. Conclusion Urease peptide combined with NP chemotherapy for the treatment of advanced re-treatment of NSCLC affirmative, toxic tolerability, especially in patients with extended median survival has some advantages.